|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003483,
umls-concept:C0034693,
umls-concept:C0034721,
umls-concept:C0035015,
umls-concept:C0205191,
umls-concept:C0205314,
umls-concept:C0679622,
umls-concept:C1280500,
umls-concept:C1373060,
umls-concept:C1533698,
umls-concept:C1708528
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2005-5-24
|
|
pubmed:abstractText |
Cytotoxic nitric oxide (NO) is produced during ischemia-reperfusion injury and acute and chronic rejection in allografts by expression of inducible (i) NO synthase (NOS). Therefore, continuous inhibition of iNOS may prevent early graft dysfunction and immune injury (rejection) and consequently improve graft survival. FR260330 is a potent and selective inhibitor of iNOS activity that works by preventing iNOS monomers from dimerization. In this study, the authors evaluated the effect of FR260330 in prevention of chronic rejection in a model of rat aortic allografts.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
0041-1337
|
|
pubmed:author |
pubmed-author:ButkoD IuDIu,
pubmed-author:ChenHuifangH,
pubmed-author:ChidaNoboruN,
pubmed-author:DalozePierreP,
pubmed-author:JiangWenleiW,
pubmed-author:OuyangJunJ,
pubmed-author:QiShijieS,
pubmed-author:SudoYujiY,
pubmed-author:TamuraKouichiK,
pubmed-author:XuDashengD,
pubmed-author:ZhangXiaochunX
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
27
|
|
pubmed:volume |
79
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1386-92
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15912108-Actins,
pubmed-meshheading:15912108-Animals,
pubmed-meshheading:15912108-Aorta,
pubmed-meshheading:15912108-Body Weight,
pubmed-meshheading:15912108-Chronic Disease,
pubmed-meshheading:15912108-Dose-Response Relationship, Drug,
pubmed-meshheading:15912108-Drug Therapy, Combination,
pubmed-meshheading:15912108-Enzyme Inhibitors,
pubmed-meshheading:15912108-Graft Rejection,
pubmed-meshheading:15912108-Graft Survival,
pubmed-meshheading:15912108-Hyperplasia,
pubmed-meshheading:15912108-Immunosuppressive Agents,
pubmed-meshheading:15912108-Male,
pubmed-meshheading:15912108-Muscle, Smooth, Vascular,
pubmed-meshheading:15912108-Myocytes, Smooth Muscle,
pubmed-meshheading:15912108-Nitric Oxide Synthase,
pubmed-meshheading:15912108-Nitric Oxide Synthase Type II,
pubmed-meshheading:15912108-Piperidines,
pubmed-meshheading:15912108-Rats,
pubmed-meshheading:15912108-Rats, Inbred ACI,
pubmed-meshheading:15912108-Rats, Inbred Lew,
pubmed-meshheading:15912108-Tacrolimus,
pubmed-meshheading:15912108-Transplantation, Homologous,
pubmed-meshheading:15912108-Tunica Intima,
pubmed-meshheading:15912108-Tunica Media
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Effect of a novel inducible nitric oxide synthase inhibitor in prevention of rat chronic aortic rejections.
|
|
pubmed:affiliation |
Laboratory of Experimental Surgery, Research Center of Centre Hospitalier de l'Université de Montréal, Notre-Dame Hospital, University of Montreal, Montreal, Quebec, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
